Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 172 | 46% |
| 2020 | 2 | 115 | 50% |
| 2021 | 2 | 149 | 53% |
| 2022 | 4 | 136 | 54% |
| 2023 | 4 | 197 | 57% |
| 2024 | 5 | 276 | 59% |
| 2025 from claims | – | 391 316–459 | 63% |
| 2026 forecast | – | 442 346–555 | 62% |
| 2027 forecast | – | 479 356–634 | 63% |
| 2028 forecast | – | 520 368–717 | 64% |
| 2029 forecast | – | 563 383–807 | 65% |
| 2030 forecast | – | 610 399–905 | 65% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Connecticut; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 70% hospital outpatient, 30% surgery center. The share outside the hospital has moved +30 pts since 2022, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,267+7.6%/yr | +7.6%/yr | 0.6 | 39% | 2,170 in 2030+9.4%/yr |
| Pennsylvania | 15 | 1,231+6.1%/yr | +6.1%/yr | 0.8 | 44% | 1,540 in 2030+3.8%/yr |
| Massachusetts | 17 | 831+11%/yr | +11%/yr | 0.8 | 6% | 820 in 2030−0.3%/yr |
| New Jersey | 8 | 739+5.9%/yr | +5.9%/yr | 0.7 | 58% | 950 in 2030+4.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 35 | 2,271−2.6%/yr | −2.6%/yr | 6.50.9× | 94% | 3,630 in 2030+8.1%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
Spr Therapeutics leads with 80% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 10 companies reported engagement with Connecticut’s surgeons worth $96K in consulting, speaking, meals and travel tied to these products, about $19K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.